Targeting polymorphonuclear myeloid‐derived suppressor cells in the immunosuppressive tumor microenvironment for cancer immunotherapy

• Published in: MedComm (2020) 2024-07, Vol.5 (7), p.e602-n/a
• Main Authors: Li, Shiqi, Long, Xinghua
• Format: Article
• Language: English
• Subjects: Cancer; Highlight; Immunotherapy
• ISSN: 2688-2663; 2688-2663
• DOI: 10.1002/mco2.602

Tumor‐driven immune suppression is a critical mechanism by which cancer cells evade the host immune system, leading to tumor growth and metastasis. The tumor immune microenvironment contains a large population of immune‐suppressing myeloid cells, which play a key role in tumor development and drug resistance to existing immunotherapy. Polymorphonuclear myeloid‐derived suppressor cells (PMN‐MDSCs) are important components of the immunosuppressive microenvironment. Uncovering the molecular mechanisms of PMN‐MDSCs and finding specific targets for PMN‐MDSCs to regulate tumor immune microenvironment is the focus and challenge of current immunotherapy. In a recent issue of Nature, Wang and colleagues revealed that CD300ld on PMN‐MDSCs is required for tumor‐driven immune suppression, this provided a new target for cancer immunotherapy, The study identified CD300ld as a novel, highly conserved tumor immunosuppressive receptor. CD300ld is highly expressed specifically on PMN‐MDSCs and is a key receptor in regulating the recruitment and immunosuppressant function of PMN‐MDSCs. Targeting CD300ld can reshape the tumor immune microenvironment by inhibiting the recruitment and function of PMN‐MDSCs, resulting in broad‐spectrum anti‐tumor effects. CD300ld target shows good safety, conservation, anti‐tumor effectiveness, and synergism with the Programmed death‐1 target, which is expected to become a new ideal target for tumor immunotherapy. The role of polymorphonuclear myelopoietic suppressor cells in immunosuppressive tumor microenvironment.